BLADDER CANCER – Sanger sequencing of the KRAS gene

LabGenetics
Caja de BLADDER CANCER – Sanger sequencing of the KRAS gene

Delivery time

3-4 weeks

Sample

Biopsy tissue

400,00€
Caja de BLADDER CANCER – Sanger sequencing of the KRAS gene

Genetic testing for bladder cancer using Sanger sequencing of the KRAS gene allows for the identification of somatic mutations associated with aberrant activation of the RAS/MAPK pathway, which is involved in cell proliferation and survival. KRAS alterations are linked to a subgroup of bladder tumors with distinct biological behavior and potential therapeutic implications. This analysis contributes to molecular diagnosis, prognostic stratification, and the development of personalized therapies.

Other tests

Preventive health test - AboutMe EXOME

Preventive health test - AboutMe EXOME

545,00€

NEUROFIBROMATOSIS: GENES SMARCB1 Y LZTR1 (NGS-Sec) – ATG Medical

NEUROFIBROMATOSIS: GENES SMARCB1 Y LZTR1 (NGS-Sec) – ATG Medical

600,00€

Custom sequencing panels (1 to 15 genes)

Custom sequencing panels (1 to 15 genes)

660,00€